+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer Biopsy Market - Global Forecast 2026-2032- Product Image
Cancer Biopsy Market - Global Forecast 2026-2032- Product Image
Sale

Cancer Biopsy Market - Global Forecast 2026-2032

  • Report

  • 196 Pages
  • July 2026
  • Region: Global
  • 360iResearch™
  • ID: 6011652
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cancer Biopsy Market is projected to reach USD 37.63 Billion in 2026. It is expected to continue growing at a CAGR of 8.44%, reaching USD 61.35 Billion by 2032.

Cancer biopsy remains a cornerstone of oncology diagnosis, staging, treatment selection, and disease monitoring. The field spans tissue biopsy, fine-needle aspiration, core needle biopsy, surgical biopsy, image-guided biopsy, liquid biopsy, circulating tumor DNA testing, and molecular pathology workflows. Demand is being shaped by the global cancer burden, earlier screening initiatives, and the expansion of precision oncology, where biomarker-driven therapy decisions increasingly depend on reliable tumor sampling and genomic characterization. Verified clinical practice patterns show that biopsy results guide tumor classification, receptor testing, mutation profiling, immunohistochemistry, next-generation sequencing, and eligibility assessment for targeted therapies and immunotherapies. At the same time, clinicians are prioritizing minimally invasive procedures, faster turnaround times, sample adequacy, patient safety, and integration between pathology, radiology, oncology, and laboratory information systems. The executive outlook for cancer biopsy is therefore defined by a shift from diagnosis alone toward a continuous, evidence-based cancer management model that connects tissue morphology, molecular data, imaging, and longitudinal monitoring.

Transformative Shifts Reshaping the Cancer Biopsy Landscape

The cancer biopsy landscape is undergoing structural transformation as oncology moves from single-point diagnosis to dynamic disease profiling. Image-guided biopsy is improving lesion targeting in lung, breast, liver, prostate, and deep-tissue tumors, while endoscopic and robotic-assisted approaches are expanding access to anatomically complex sites. Molecular testing is also changing specimen requirements, making pre-analytical quality, fixation protocols, tumor cellularity, and nucleic acid preservation critical operational priorities. Liquid biopsy is gaining clinical relevance for selected use cases such as mutation detection, minimal residual disease research, resistance monitoring, and recurrence surveillance, particularly when tissue access is limited or repeat sampling is clinically challenging. Regulatory scrutiny, quality accreditation, and evidence requirements are pushing laboratories toward validated assays, standardized reporting, and traceable workflows. Healthcare systems are also emphasizing multidisciplinary tumor boards, digital pathology adoption, interoperability, and decentralized sample collection models. These shifts are elevating cancer biopsy from a procedural service into a data-intensive diagnostic platform that supports personalized treatment pathways.

Cumulative Impact of Artificial Intelligence on Cancer Biopsy

Artificial intelligence is creating cumulative impact across the cancer biopsy continuum by improving planning, sampling, pathology interpretation, workflow efficiency, and data integration. In radiology, AI-enabled image analysis can support lesion detection, segmentation, biopsy route planning, and prioritization of suspicious findings, although physician oversight and validation remain essential. In pathology, computational tools are being evaluated and deployed to assist with tumor detection, grading support, mitotic count estimation, immunohistochemistry quantification, biomarker scoring, and digital slide triage. AI can also help identify insufficient or low-quality samples earlier in the workflow, reducing repeat procedures and accelerating downstream molecular testing. In molecular diagnostics, machine learning is being applied to variant interpretation, ctDNA signal analysis, assay quality control, and integration of genomic results with clinical context. The practical value of AI in cancer biopsy depends on curated datasets, clinically representative training cohorts, explainability, cybersecurity, regulatory compliance, and continuous performance monitoring. As adoption matures, AI is expected to function less as a replacement for specialists and more as an augmentation layer that strengthens consistency, speed, and diagnostic confidence.

Key Regional Insights Across Global Cancer Biopsy Adoption

Asia-Pacific is experiencing rapid advancement in cancer biopsy capabilities as China, India, Japan, South Korea, and Australia expand oncology infrastructure, molecular diagnostics access, and digital health programs. The region faces a substantial cancer burden and wide variability in healthcare access, making cost-efficient tissue biopsy, liquid biopsy, and centralized laboratory models important for both urban and underserved populations. Europe benefits from coordinated cancer plans, quality-driven laboratory networks, and growing use of molecular tumor boards, with emphasis on harmonized testing standards, data protection, and equitable access across member and non-member countries. North America is characterized by strong adoption of precision oncology, established pathology accreditation practices, extensive use of image-guided procedures, and broad clinical integration of biomarker testing across major tumor types. Latin America is strengthening cancer diagnosis capacity through public and private investments in pathology modernization, though uneven reimbursement, specimen logistics, and specialist availability remain persistent challenges. Africa continues to face constraints in pathology workforce, biopsy access, sample transport, and molecular testing availability, but regional cancer control strategies, telepathology pilots, and international training collaborations are supporting incremental improvements in diagnostic capacity. The Middle East is investing in tertiary oncology centers, genomic medicine initiatives, and medical tourism infrastructure, particularly in high-income Gulf economies, while access gaps remain across lower-resource settings.

Key Group Insights for Cancer Biopsy Development

NATO countries overlap significantly with North American and European diagnostic systems, where defense-related medical networks, civilian healthcare infrastructure, and cross-border standards contribute to resilience, interoperability, and innovation in cancer diagnostics. G7 countries generally demonstrate mature biopsy ecosystems supported by specialist workforces, reimbursement structures, advanced imaging, genomic testing, and strong clinical research activity. BRICS economies represent diverse but influential cancer biopsy environments: China and India are expanding high-volume diagnostic capacity, Brazil and South Africa are working to improve public-sector access and pathology coverage, and Russia maintains established specialist oncology networks with increasing molecular testing activity. The European Union is advancing cancer biopsy quality through regulatory harmonization, cross-border research, molecular diagnostics standards, and cancer mission initiatives that support earlier detection and personalized medicine. ASEAN countries are prioritizing scalable cancer diagnostic pathways as rising cancer incidence, urban hospital expansion, and national screening programs increase demand for biopsy services, although access differs markedly between Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines. GCC health systems are investing in advanced oncology centers, genomic testing, and digital pathology infrastructure, supported by national health transformation agendas and a high dependence on specialized tertiary care.

Key Country Insights Shaping Cancer Biopsy Practices

China is rapidly scaling cancer biopsy and genomic testing capacity through hospital expansion, domestic assay development, and large oncology centers. The United States leads in broad clinical use of biomarker-driven cancer biopsy workflows, supported by advanced oncology networks, accredited laboratories, image-guided biopsy availability, and integration of tissue and liquid biopsy into treatment decision-making. Japan demonstrates high-quality pathology standards, advanced imaging-guided biopsy practices, and strong adoption of companion diagnostics. India is advancing biopsy access through tertiary cancer institutes, private diagnostics, and expanding molecular pathology, while affordability and rural access remain central challenges. Germany has a strong pathology and laboratory medicine base, high procedural quality, and extensive molecular diagnostics expertise. The United Kingdom benefits from national cancer pathways, centralized genomic laboratory networks, and established multidisciplinary team models. Australia combines organized cancer care, strong pathology governance, and regional telehealth models to support access beyond metropolitan centers. France supports precision oncology through national cancer strategies, molecular testing platforms, and structured care networks. South Korea is distinguished by advanced hospital infrastructure, high technology adoption, national screening activity, and strong integration of molecular diagnostics into oncology care. Italy and Spain have well-developed hospital-based biopsy services, active oncology research communities, and growing digital pathology and molecular testing adoption. Canada emphasizes publicly funded cancer care, provincial testing pathways, and quality-focused pathology services, while geographic dispersion can affect timely access in remote communities. Russia maintains specialized oncology institutions and biopsy capability across major regions, with ongoing emphasis on modernizing molecular diagnostics. Brazil has significant cancer care capacity in large cities and leading academic hospitals, though public-sector access and turnaround time challenges persist across regions. Mexico is expanding oncology diagnostics through public institutions and private providers, with improving access to image-guided biopsy and molecular testing in major urban centers.

Actionable Recommendations for Cancer Biopsy Industry Leaders

Industry leaders should prioritize clinically validated, workflow-compatible cancer biopsy solutions that improve diagnostic accuracy, sample adequacy, and turnaround time without increasing procedural complexity. Strategic focus should include strengthening partnerships with oncology centers, radiology departments, pathology laboratories, and molecular diagnostic providers to create end-to-end biopsy pathways. Organizations should invest in specimen quality controls, standardized pre-analytical protocols, digital pathology readiness, AI governance frameworks, and interoperable data systems that connect imaging, pathology, genomics, and electronic health records. For liquid biopsy and molecular testing, leaders should align claims with peer-reviewed clinical evidence, clear intended use, and regulatory expectations. Access strategies must address affordability, reimbursement documentation, workforce training, and decentralized sample logistics, especially in emerging health systems. To build long-term credibility, industry participants should support clinician education, proficiency testing, external quality assessment, real-world evidence generation, and transparent reporting standards. Competitive advantage will come from enabling reliable, minimally invasive, data-rich cancer diagnosis that fits existing oncology workflows and supports precision treatment decisions.

Research Methodology for Evidence-Based Cancer Biopsy Insights

This executive summary is developed using a structured secondary research approach focused on verified, data-backed sources, including public health agencies, cancer registries, clinical guideline bodies, peer-reviewed medical literature, regulatory documents, pathology accreditation standards, and oncology policy publications. The methodology emphasizes triangulation of evidence across epidemiology, diagnostic practice, technology adoption, clinical workflow, and regional healthcare infrastructure. Insights are assessed for relevance to cancer biopsy procedures, tissue and liquid biopsy applications, molecular diagnostics, artificial intelligence, digital pathology, and precision oncology. Qualitative synthesis is used to identify transformation themes, regional variations, clinical adoption drivers, access barriers, and operational priorities. The analysis intentionally excludes market estimation, market sizing, market share, and forecasting. All findings are framed to support executive decision-making while maintaining alignment with evidence-based medicine, regulatory expectations, and real-world healthcare delivery conditions.

Conclusion: Cancer Biopsy as a Foundation of Personalized Cancer Care

Cancer biopsy is evolving into a central platform for precision oncology, linking procedural diagnostics with pathology, genomics, imaging, artificial intelligence, and longitudinal treatment monitoring. The strongest opportunities are emerging where healthcare systems can combine minimally invasive sampling, high-quality tissue handling, validated molecular assays, digital pathology, and multidisciplinary interpretation. Regional and country-level differences remain significant, especially in access to specialist pathology, molecular testing, reimbursement, and sample logistics. However, global momentum is clear: cancer care increasingly depends on accurate, timely, and data-rich biopsy results. Organizations that focus on clinical validation, workflow integration, quality assurance, equitable access, and responsible AI adoption will be best positioned to support the next generation of cancer diagnosis and personalized treatment.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Cancer Biopsy Market, by Biopsy Type
7.1. Introduction
7.2. Surgical Biopsy
7.2.1. Incisional
7.2.2. Excisional
7.3. Needle Biopsy
7.3.1. Fine Needle Aspiration Biopsy
7.3.2. Core Needle Biopsy
7.4. Liquid Biopsy
7.4.1. Circulating Tumor Cells
7.4.2. Cell Free DNA
7.4.3. Exosomes
7.5. Bone Marrow Biopsy
7.6. Skin Biopsy
7.6.1. Punch
7.6.2. Shave
8. Cancer Biopsy Market, by Cancer Type
8.1. Introduction
8.2. Breast Cancer
8.3. Lung Cancer
8.4. Prostate Cancer
8.5. Colorectal Cancer
8.6. Blood Cancer
8.7. Liver Cancer
8.8. Kidney Cancer
9. Cancer Biopsy Market, by Technology
9.1. Introduction
9.2. Imaging Guided Biopsy
9.3. Manual Freehand Biopsy
9.4. Robotic Assisted Biopsy
10. Cancer Biopsy Market, by Sample Type
10.1. Introduction
10.2. Tissue Biopsy Samples
10.3. Liquid Biopsy Samples
10.3.1. Blood Plasma
10.3.2. Serum
10.3.3. Urine
11. Cancer Biopsy Market, by Application
11.1. Introduction
11.2. Diagnosis
11.3. Prognosis
11.4. Treatment Selection
11.5. Disease Monitoring
11.6. Recurrence Detection
12. Cancer Biopsy Market, by End User
12.1. Introduction
12.2. Ambulatory Surgical Centers
12.3. Diagnostic Imaging Centers
12.4. Hospitals
12.4.1. Private
12.4.2. Public
12.5. Physicians Offices
13. Cancer Biopsy Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East
14. Cancer Biopsy Market, by Group
14.1. NATO
14.2. G7
14.3. BRICS
14.4. European Union
14.5. ASEAN
14.6. GCC
15. Cancer Biopsy Market, by Country
15.1. China
15.2. United States
15.3. Japan
15.4. India
15.5. Germany
15.6. United Kingdom
15.7. Australia
15.8. France
15.9. South Korea
15.10. Italy
15.11. Canada
15.12. Russia
15.13. Brazil
15.14. Mexico
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Agilent Technologies, Inc.
17.2. Amoy Diagnostics Co., Ltd.
17.3. ANGLE plc
17.4. Becton, Dickinson and Company
17.5. Bio-Rad Laboratories, Inc.
17.6. Biocept, Inc.
17.7. Biodesix, Inc.
17.8. Caris Life Sciences, Inc.
17.9. Danaher Corporation
17.10. Exact Sciences Corporation
17.11. F. Hoffmann-La Roche Ltd.
17.12. GRAIL, Inc.
17.13. Guardant Health, Inc.
17.14. Hologic, Inc.
17.15. Illumina, Inc.
17.16. Laboratory Corporation of America Holdings
17.17. Lucence Health Inc.
17.18. MDxHealth SA
17.19. Myriad Genetics, Inc.
17.20. Natera, Inc.
17.21. NeoGenomics Laboratories, Inc.
17.22. Personal Genome Diagnostics Inc.
17.23. QIAGEN N.V.
17.24. Quest Diagnostics Incorporated
17.25. Siemens Healthineers AG
17.26. Sysmex Corporation
17.27. Thermo Fisher Scientific Inc.
17.28. Veracyte, Inc.
List of Figures
FIGURE 1. GLOBAL CANCER BIOPSY MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL CANCER BIOPSY MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL CANCER BIOPSY MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL CANCER BIOPSY MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL CANCER BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL CANCER BIOPSY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL CANCER BIOPSY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL CANCER BIOPSY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL CANCER BIOPSY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL CANCER BIOPSY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL CANCER BIOPSY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL CANCER BIOPSY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL CANCER BIOPSY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL CANCER BIOPSY MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL CANCER BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL SURGICAL BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL SURGICAL BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL SURGICAL BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL INCISIONAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL INCISIONAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL INCISIONAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL EXCISIONAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL EXCISIONAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL EXCISIONAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL NEEDLE BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL NEEDLE BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL NEEDLE BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL FINE NEEDLE ASPIRATION BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL FINE NEEDLE ASPIRATION BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL FINE NEEDLE ASPIRATION BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL CORE NEEDLE BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL CORE NEEDLE BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL CORE NEEDLE BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL LIQUID BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL CIRCULATING TUMOR CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL CIRCULATING TUMOR CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL CIRCULATING TUMOR CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL CELL FREE DNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL CELL FREE DNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL CELL FREE DNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL EXOSOMES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL EXOSOMES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL EXOSOMES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL BONE MARROW BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL BONE MARROW BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL BONE MARROW BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL SKIN BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL SKIN BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL SKIN BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL PUNCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL PUNCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL PUNCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL SHAVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL SHAVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL SHAVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL BLOOD CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL BLOOD CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL BLOOD CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL LIVER CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL LIVER CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL LIVER CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL KIDNEY CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL KIDNEY CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL KIDNEY CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL IMAGING GUIDED BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL IMAGING GUIDED BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL IMAGING GUIDED BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL MANUAL FREEHAND BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL MANUAL FREEHAND BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL MANUAL FREEHAND BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL ROBOTIC ASSISTED BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL ROBOTIC ASSISTED BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL ROBOTIC ASSISTED BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL TISSUE BIOPSY SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL TISSUE BIOPSY SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL TISSUE BIOPSY SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL LIQUID BIOPSY SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL LIQUID BIOPSY SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL LIQUID BIOPSY SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL BLOOD PLASMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL BLOOD PLASMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL BLOOD PLASMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL SERUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL SERUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL SERUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL URINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL URINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL PROGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL PROGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL PROGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL TREATMENT SELECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL TREATMENT SELECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL TREATMENT SELECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL DISEASE MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL DISEASE MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL DISEASE MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL RECURRENCE DETECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL RECURRENCE DETECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL RECURRENCE DETECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL DIAGNOSTIC IMAGING CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL DIAGNOSTIC IMAGING CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL DIAGNOSTIC IMAGING CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL PRIVATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL PRIVATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL PRIVATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL PUBLIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL PUBLIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL PUBLIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL PHYSICIANS OFFICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL PHYSICIANS OFFICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL PHYSICIANS OFFICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL CANCER BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 143. EUROPE CANCER BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 144. EUROPE CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
TABLE 145. EUROPE CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
TABLE 146. EUROPE CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
TABLE 147. EUROPE CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 148. EUROPE CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
TABLE 149. EUROPE CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 150. EUROPE CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 151. EUROPE CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 152. EUROPE CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
TABLE 153. EUROPE CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 154. EUROPE CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 155. EUROPE CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 156. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 157. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
TABLE 158. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
TABLE 159. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
TABLE 160. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 161. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
TABLE 162. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 163. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 164. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 165. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
TABLE 166. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 167. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 168. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 169. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 170. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
TABLE 171. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
TABLE 172. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
TABLE 173. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 174. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
TABLE 175. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 176. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 177. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 178. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
TABLE 179. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 180. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 181. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 182. AFRICA CANCER BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 183. AFRICA CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
TABLE 184. AFRICA CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
TABLE 185. AFRICA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
TABLE 186. AFRICA CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 187. AFRICA CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
TABLE 188. AFRICA CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 189. AFRICA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 190. AFRICA CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 191. AFRICA CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
TABLE 192. AFRICA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 193. AFRICA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 194. AFRICA CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 195. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 196. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
TABLE 197. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
TABLE 198. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
TABLE 199. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 200. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
TABLE 201. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 202. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 203. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 204. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
TABLE 205. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 206. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 207. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 208. GLOBAL CANCER BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 209. NATO CANCER BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 210. NATO CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
TABLE 211. NATO CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
TABLE 212. NATO CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
TABLE 213. NATO CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 214. NATO CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
TABLE 215. NATO CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 216. NATO CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 217. NATO CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 218. NATO CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
TABLE 219. NATO CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 220. NATO CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 221. NATO CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 222. G7 CANCER BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 223. G7 CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
TABLE 224. G7 CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
TABLE 225. G7 CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
TABLE 226. G7 CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 227. G7 CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
TABLE 228. G7 CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 229. G7 CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 230. G7 CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 231. G7 CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
TABLE 232. G7 CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 233. G7 CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 234. G7 CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 235. BRICS CANCER BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 236. BRICS CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
TABLE 237. BRICS CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
TABLE 238. BRICS CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
TABLE 239. BRICS CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 240. BRICS CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
TABLE 241. BRICS CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 242. BRICS CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 243. BRICS CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 244. BRICS CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
TABLE 245. BRICS CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 246. BRICS CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 247. BRICS CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 248. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 249. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
TABLE 250. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
TABLE 251. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
TABLE 252. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 253. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
TABLE 254. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 255. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 256. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 257. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
TABLE 258. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 259. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 260. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 261. ASEAN CANCER BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 262. ASEAN CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
TABLE 263. ASEAN CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
TABLE 264. ASEAN CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
TABLE 265. ASEAN CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 266. ASEAN CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
TABLE 267. ASEAN CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 268. ASEAN CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 269. ASEAN CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 270. ASEAN CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
TABLE 271. ASEAN CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 272. ASEAN CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 273. ASEAN CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 274. GCC CANCER BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 275. GCC CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
TABLE 276. GCC CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
TABLE 277. GCC CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
TABLE 278. GCC CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 279. GCC CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
TABLE 280. GCC CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 281. GCC CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 282. GCC CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 283. GCC CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
TABLE 284. GCC CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 285. GCC CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 286. GCC CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 287. GLOBAL CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 288. CHINA CANCER BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 289. CHINA CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
TABLE 290. CHINA CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
TABLE 291. CHINA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
TABLE 292. CHINA CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 293. CHINA CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
TABLE 294. CHINA CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 295. CHINA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 296. CHINA CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 297. CHINA CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
TABLE 298. CHINA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 299. CHINA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 300. CHINA CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 301. UNITED STATES CANCER BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 302. UNITED STATES CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
TABLE 303. UNITED STATES CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
TABLE 304. UNITED STATES CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
TABLE 305. UNITED STATES CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 306. UNITED STATES CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
TABLE 307. UNITED STATES CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 308. UNITED STATES CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 309. UNITED STATES CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 310. UNITED STATES CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
TABLE 311. UNITED STATES CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 312. UNITED STATES CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 313. UNITED STATES CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 314. JAPAN CANCER BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 315. JAPAN CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
TABLE 316. JAPAN CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
TABLE 317. JAPAN CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
TABLE 318. JAPAN CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 319. JAPAN CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
TABLE 320. JAPAN CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 321. JAPAN CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 322. JAPAN CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 323. JAPAN CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
TABLE 324. JAPAN CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 325. JAPAN CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 326. JAPAN CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 327. INDIA CANCER BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 328. INDIA CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
TABLE 329. INDIA CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
TABLE 330. INDIA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
TABLE 331. INDIA CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 332. INDIA CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
TABLE 333. INDIA CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 334. INDIA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 335. INDIA CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 336. INDIA CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
TABLE 337. INDIA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 338. INDIA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 339. INDIA CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 340. GERMANY CANCER BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 341. GERMANY CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
TABLE 342. GERMANY CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
TABLE 343. GERMANY CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
TABLE 344. GERMANY CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 345. GERMANY CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
TABLE 346. GERMANY CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 347. GERMANY CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 348. GERMANY CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 349. GERMANY CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
TABLE 350. GERMANY CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 351. GERMANY CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 352. GERMANY CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 353. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 354. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
TABLE 355. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
TABLE 356. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
TABLE 357. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 358. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
TABLE 359. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 360. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 361. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 362. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
TABLE 363. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 364. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 365. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 366. AUSTRALIA CANCER BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 367. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
TABLE 368. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
TABLE 369. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
TABLE 370. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 371. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
TABLE 372. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 373. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 374. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 375. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
TABLE 376. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 377. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 378. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 379. FRANCE CANCER BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 380. FRANCE CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
TABLE 381. FRANCE CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
TABLE 382. FRANCE CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
TABLE 383. FRANCE CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 384. FRANCE CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
TABLE 385. FRANCE CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 386. FRANCE CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)

Companies Mentioned

  • Agilent Technologies, Inc.
  • Amoy Diagnostics Co., Ltd.
  • ANGLE plc
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biocept, Inc.
  • Biodesix, Inc.
  • Caris Life Sciences, Inc.
  • Danaher Corporation
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • GRAIL, Inc.
  • Guardant Health, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • Lucence Health Inc.
  • MDxHealth SA
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • NeoGenomics Laboratories, Inc.
  • Personal Genome Diagnostics Inc.
  • QIAGEN N.V.
  • Quest Diagnostics Incorporated
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Veracyte, Inc.

Table Information

Report AttributeDetails
No. of Pages196
PublishedJuly 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 37.63 Billion
Forecasted Market Value ( USD ) by 2032 $ 61.35 Billion
Compound Annual Growth Rate8.4%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

Breast Biopsy Market - Global Forecast 2026-2032 - Product Image

Breast Biopsy Market - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From
Smart Biopsy Devices Market by Technology Type, Component, Procedure Type, Automation Level, Application, End User - Global Forecast 2026-2032 - Product Image

Smart Biopsy Devices Market by Technology Type, Component, Procedure Type, Automation Level, Application, End User - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Fusion Biopsy - Global Strategic Business Report - Product Image

Fusion Biopsy - Global Strategic Business Report

  • Report
  • 277 Pages
  • Global
From
Biopsy Devices Market Report by Procedure Type, Product, Application, Guidance Technique, End User, and Region 2026-2034 - Product Image

Biopsy Devices Market Report by Procedure Type, Product, Application, Guidance Technique, End User, and Region 2026-2034

  • Report
  • 140 Pages
  • Global
From
Fusion Biopsy - Market Insights, Competitive Landscape, and Market Forecast - 2034 - Product Image

Fusion Biopsy - Market Insights, Competitive Landscape, and Market Forecast - 2034

  • Report
  • 150 Pages
  • Global
From

About the Market

The Cancer Biopsy market within the In Vitro Diagnostics (IVD) industry is a rapidly growing sector. It is used to detect and diagnose cancer in patients, and is a key component of the IVD industry. Cancer biopsy tests are used to detect the presence of cancer cells in a sample of tissue taken from the patient. The sample is then analyzed to determine the type and stage of cancer. The results of the biopsy can help guide treatment decisions. The Cancer Biopsy market is driven by the increasing prevalence of cancer, advances in technology, and the growing demand for early diagnosis and treatment. The market is expected to continue to grow in the coming years, as more advanced tests become available and the demand for early diagnosis and treatment increases. Some of the major companies in the Cancer Biopsy market include Abbott Laboratories, Becton Dickinson, Cepheid, Hologic, and Roche Diagnostics. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.